<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T15:04:51Z</responseDate><request verb="GetRecord" identifier="oai:digital.lib.washington.edu:1773/51385" metadataPrefix="dim">https://digital.lib.washington.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:digital.lib.washington.edu:1773/51385</identifier><datestamp>2026-02-15T21:17:11Z</datestamp><setSpec>com_1773_4888</setSpec><setSpec>col_1773_4943</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Olson, James</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" authority="7228c48c-840e-4845-b2c3-8699a846b749" confidence="300">Noll, Alyssa</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2024-04-26T23:22:08Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2024-04-26</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="submitted">2024</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">Noll_washington_0250E_26533.pdf</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/1773/51385</dim:field>
   <dim:field mdschema="dc" element="description">Thesis (Ph.D.)--University of Washington, 2024</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Neuroblastoma, a cancer of the sympathetic nervous system, is the most common extracranial solid tumor in children, representing 10% of all pediatric malignancies. Despite 
aggressive treatment with intensive multi-modal therapies, most children with high-risk 
neuroblastoma will relapse, so novel therapeutic approaches are desperately needed. 
Immunotherapies have risen to the forefront of cancer treatments, exemplified by the ability of 
checkpoint inhibitors to induce anti-tumor responses in adult cancers refractory to conventional
treatments. However, children with cancer, including those with neuroblastoma, have failed to
benefit from these advances, attributed to intrinsic mechanisms of immune evasion. Thus, 
neuroblastoma presents a challenge that may serve as a model for the application of 
immunotherapies for other “immunologically cold” pediatric tumors. 
Bispecific T cell engaging antibodies are engineered proteins designed to 
simultaneously bind a tumor specific antigen and CD3 on T cells, thereby instructing 
endogenous lymphocytes to destroy the bridged tumor cell. Bispecific T cell Engagers (BTEs)
are a rapidly evolving approach to treating cancer, with the number of clinically approved BTEs 
jumping from 1 to 8 since 2022. Although one BTE, blinatumomab, has improved outcomes in
pediatric leukemia, the application of BTEs to pediatric solid tumors has proved challenging in 
part due to a scarcity of tumor-specific antigens.
To identify potential neuroblastoma antigens suitable for BTE immunotherapy, we 
screened a diverse panel of neuroblastoma cell lines and identified B7H3, a surface protein with 
reported roles in immune evasion, as a candidate target. B7H3 overexpression was validated in 
high-risk neuroblastoma patient samples compared to adjacent peripheral tissues. 
Although there are over 100 distinct BTEs in preclinical development, few published 
works have directly compared different BTE designs and CD3 engagers. We designed, 
produced, and evaluated a suite of unique B7H3-CD3 BTEs to investigate the role of BTE 
architecture and CD3 affinity on the function of BTEs in vitro. We found that IgG-like BTEs with 
anti-CD3 scFvs linked to the carboxy-termini of the IgG light chains mediated potent anti-tumor 
activity in vitro, attributed to their bivalency for both B7H3 and CD3. This format, termed IgG-L-scFv, demonstrated an increase in potency with an increase in CD3 affinity, and yet 
demonstrated strictly target-dependent activity. From these studies, we identified a B7H3MGA271-
CD3ADI24 IgG-L-scFv as the lead candidate BTE. Despite the promising potency of this molecule
in functional assays, in neuroblastoma xenograft models, we found that efficacy was limited by 
insufficient recruitment of T cells in circulation. This finding highlights a crucial barrier to the 
application of BTEs and other T-cell targeting immunotherapies to neuroblastoma and by 
extension other pediatric solid tumors. A deeper understanding of the mechanisms regulating T 
cell trafficking may guide future development of immunotherapeutic strategies for children with 
high-risk neuroblastoma.</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en_US</dim:field>
   <dim:field mdschema="dc" element="rights">CC BY</dim:field>
   <dim:field mdschema="dc" element="subject">B7H3</dim:field>
   <dim:field mdschema="dc" element="subject">bispecific antibody</dim:field>
   <dim:field mdschema="dc" element="subject">bispecific T cell engager</dim:field>
   <dim:field mdschema="dc" element="subject">neuroblastoma</dim:field>
   <dim:field mdschema="dc" element="subject">Molecular biology</dim:field>
   <dim:field mdschema="dc" element="subject">Oncology</dim:field>
   <dim:field mdschema="dc" element="subject">Immunology</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="other">Molecular and cellular biology</dim:field>
   <dim:field mdschema="dc" element="title">Design and Evaluation of Bispecific T cell Engaging Antibodies for the Treatment of  Neuroblastoma</dim:field>
   <dim:field mdschema="dc" element="type">Thesis</dim:field>
   <dim:field mdschema="dc" element="embargo" qualifier="terms">Delay release for 1 year -- then make Open Access</dim:field>
   <dim:field mdschema="dc" element="embargo" qualifier="lift">2025-04-26T23:22:08Z</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>